Not Signed In - Kosan's Hsp90 Inhibitor, Tanespimycin, Shows Promising Antitumor Activity In Phase 2 Trial Of Patients With HER2-Positive Metastatic Breast Cancer
Fri, 15 Dec 2006 08:00 AM EST
... Kosan Biosciences Incorporated (Nasdaq: KOSN) today presented preliminary data from a Phase 2 clinical trial showing that tanespimycin (KOS-953) in combination with trastuzumab (Herceptin(R)) demonstrated clinically meaningful antitumor activity, including both partial responses and extended [click link for full article] ...
Related Topics
- Clinical Trials
- Metastatic Cancer
- Breast Cancer
- Brain Cancer
- Liver Cancer
- Bone Cancer
- Pancreatic Cancer
- Physical Activity
- Thyroid Cancer
- Breast Lumps & Other Breast Conditions
- Cancers
- Bladder Cancer
- Prostate Cancer
- Breast Cancer, Male
- Male Breast Cancer
- Cancer--Living with Cancer
- Breast Reconstruction
- Kidney Cancer
- Mammograms
- Colon Cancer
email this page
print this page
bookmark this page
feedback on this page
